Ernst is a business-orientated scientist with broad scientific training in oncology, infectious diseases and chemistry with a strong interest in valorization of science. Ernst holds a PhD in molecular cancer genetics from the Netherlands Cancer Institute (NKI-AvL). He then continued his career as business developer at TNO, where he gained experience in marketing, business consultancy, international business development and venturing. He had a major role in spinning-out technologies from the Earth, Environmental and Life Sciences department. He currently works as associate at Aglaia BioMedical Ventures, a venture capital firm with a focus in oncology diagnostics and therapeutics. Aglaia identifies groundbreaking opportunities in cancer research and, in close partnerships with inventors and entrepreneurs, takes these opportunities to the next phase of technical and commercial development. At Aglaia, Ernst is responsible for analysis of investment proposals as well scouting for new investment opportunities.
ISA Pharmaceuticals and Regeneron Announce Strategic Immuno-Oncology Collaboration
Cristal Therapeutics awarded €2.5 million Horizon 2020 grant to advance its CriPec®-docetaxel through Phase 2 trials